ABSK 061
Alternative Names: ABSK-061Latest Information Update: 28 Aug 2025
At a glance
- Originator Abbisko Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Achondroplasia
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (PO)
- 23 Jul 2025 Phase-I/II clinical trials in Achondroplasia in China (PO)
- 17 May 2025 Abbisko Therapeutics initiates enrolment in a phase I Pharmacokinetics trial for Healthy partcipants in China (NCT07007546)